drugset / Trial / NCT00235794
An Open Label Exploratory Study in Newly Diagnosed Prostate Cancer Patients
Non-randomizedSingle-groupOpen-labelPrevention
Summary
Open-label exloratory pharmacodynamic and pharmacogenomic study to evaluate teh biologic effects of 3 dose levels (1mg, 5 mg, and 15 mg) of temsirolimus administered orally once daily for approximately 4 weeks (+/- 2 weeks) before prostatectomy
Timeline
- Start
- 2004-01
- Primary completion
- —
- Completion
- 2007-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Temsirolimus | Small molecule | 1 mg | Oral |
| Subject | Temsirolimus | Small molecule | 5 mg | Oral |
| Subject | Temsirolimus | Small molecule | 15 mg | Oral |